Literature DB >> 25450580

mTOR signaling in tumorigenesis.

Kai Xu1, Pengda Liu2, Wenyi Wei3.   

Abstract

mTOR (the mechanistic target of rapamycin) is an atypical serine/threonine kinase involved in regulating major cellular functions including growth and proliferation. Deregulation of the mTOR signaling pathway is one of the most commonly observed pathological alterations in human cancers. To this end, oncogenic activation of the mTOR signaling pathway contributes to cancer cell growth, proliferation and survival, highlighting the potential for targeting the oncogenic mTOR pathway members as an effective anti-cancer strategy. In order to do so, a thorough understanding of the physiological roles of key mTOR signaling pathway components and upstream regulators would guide future targeted therapies. Thus, in this review, we summarize available genetic mouse models for mTORC1 and mTORC2 components, as well as characterized mTOR upstream regulators and downstream targets, and assign a potential oncogenic or tumor suppressive role for each evaluated molecule. Together, our work will not only facilitate the current understanding of mTOR biology and possible future research directions, but more importantly, provide a molecular basis for targeted therapies aiming at key oncogenic members along the mTOR signaling pathway.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mouse model; Tumorigenesis; mTOR pathway; mTORC1; mTORC2

Mesh:

Substances:

Year:  2014        PMID: 25450580      PMCID: PMC4261029          DOI: 10.1016/j.bbcan.2014.10.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  253 in total

1.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

3.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.

Authors:  W S Chen; P Z Xu; K Gottlob; M L Chen; K Sokol; T Shiyanova; I Roninson; W Weng; R Suzuki; K Tobe; T Kadowaki; N Hay
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

4.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features.

Authors:  Elizabeth Yuan; Peter T Tsai; Emily Greene-Colozzi; Mustafa Sahin; David J Kwiatkowski; Izabela A Malinowska
Journal:  Hum Mol Genet       Date:  2012-06-29       Impact factor: 6.150

6.  Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.

Authors:  John N Hutchinson; Jing Jin; Robert D Cardiff; Jim R Woodgett; William J Muller
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

7.  Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.

Authors:  Alfredo Toschi; Evan Lee; Limei Xu; Avalon Garcia; Noga Gadir; David A Foster
Journal:  Mol Cell Biol       Date:  2008-12-29       Impact factor: 4.272

8.  Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c.

Authors:  Guosheng Liang; Jian Yang; Jay D Horton; Robert E Hammer; Joseph L Goldstein; Michael S Brown
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

9.  Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2.

Authors:  Constantinos Demetriades; Nikolaos Doumpas; Aurelio A Teleman
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

10.  Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo.

Authors:  Nicole R Murray; Lee Jamieson; Wangsheng Yu; Jie Zhang; Yesim Gökmen-Polar; Deborah Sier; Panos Anastasiadis; Zoran Gatalica; E Aubrey Thompson; Alan P Fields
Journal:  J Cell Biol       Date:  2004-03-15       Impact factor: 10.539

View more
  62 in total

Review 1.  mTOR function and therapeutic targeting in breast cancer.

Authors:  Stephen H Hare; Amanda J Harvey
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  GLIS3 is indispensable for TSH/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation.

Authors:  Hong Soon Kang; Dhirendra Kumar; Grace Liao; Kristin Lichti-Kaiser; Kevin Gerrish; Xiao-Hui Liao; Samuel Refetoff; Raja Jothi; Anton M Jetten
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

Review 3.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

4.  URI knockdown induces autophagic flux in gastric cancer cells.

Authors:  Fei Zhang; Xiaoxia Hu; Yu Gu; Huiqin Bian; Zhonghai Xu; Qian Wang; Jinnan Chen; Yaojuan Lu; Lichuan Sun; Qiping Zheng; Junxia Gu
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

5.  Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.

Authors:  Jinfang Zhang; Kai Xu; Pengda Liu; Yan Geng; Bin Wang; Wenjian Gan; Jianping Guo; Fei Wu; Y Rebecca Chin; Christian Berrios; Evan C Lien; Alex Toker; James A DeCaprio; Piotr Sicinski; Wenyi Wei
Journal:  Mol Cell       Date:  2016-05-26       Impact factor: 17.970

6.  Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock.

Authors:  Yuan Zhang; Sylvie Giacchetti; Alexandre Parouchev; Eva Hadadi; Xiaomei Li; Robert Dallmann; Helena Xandri-Monje; Lucie Portier; René Adam; Françis Lévi; Sandrine Dulong; Yunhua Chang
Journal:  Cell Cycle       Date:  2018-01-02       Impact factor: 4.534

Review 7.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

Review 8.  Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer.

Authors:  Maxwell Shulman; Rachel Shi; Qing Zhang
Journal:  J Genet Genomics       Date:  2021-07-09       Impact factor: 5.723

9.  mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Authors:  David R Driscoll; Saadia A Karim; Makoto Sano; David M Gay; Wright Jacob; Jun Yu; Yusuke Mizukami; Aarthi Gopinathan; Duncan I Jodrell; T R Jeffry Evans; Nabeel Bardeesy; Michael N Hall; Brian J Quattrochi; David S Klimstra; Simon T Barry; Owen J Sansom; Brian C Lewis; Jennifer P Morton
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

10.  The Transcription Factor p8 Regulates Autophagy in Response to Palmitic Acid Stress via a Mammalian Target of Rapamycin (mTOR)-independent Signaling Pathway.

Authors:  Sheng-Nan Jia; Cheng Lin; Dian-Fu Chen; An-Qi Li; Li Dai; Li Zhang; Ling-Ling Zhao; Jin-Shu Yang; Fan Yang; Wei-Jun Yang
Journal:  J Biol Chem       Date:  2016-01-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.